Doxapram for the prevention and treatment of apnea in preterm infants-Reference-Cited by-同舟云学术

Doxapram for the prevention and treatment of apnea in preterm infants

Published:2022-03-15 Issue:3 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Evans Shannon¹,Berg Marie²,Bruschettini Matteo³⁴,Soll Roger⁵

Affiliation:

1. Neonatal-Perinatal Medicine; Norton Children’s Neonatology, affiliated with the University of Louisville School of Medicine; Louisville Kentucky USA

2. Pediatrics/Neonatology; Johns Hopkins All Children's Hospital; St. Petersburg Florida USA

3. Department of Clinical Sciences Lund, Paediatrics; Lund University, Skåne University Hospital; Lund Sweden

4. Cochrane Sweden, Lund University, Skåne University Hospital; Lund Sweden

5. Division of Neonatal-Perinatal Medicine, Department of Pediatrics; Larner College of Medicine at the University of Vermont; Burlington Vermont USA

Publisher

Wiley

Subject

Pharmacology (medical)

Reference78 articles.

1. Apnea, sudden infant death syndrome, and home monitoring;Committee on Fetus and Newborn American Academy of Pediatrics;Pediatrics,2003

2. A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity;Al-Saif;Journal of Pediatrics,2008

3. Gastrointestinal absorption of doxapram in neonates;Bairam;American Journal of Perinatology,1991

4. Infant functional status: the timing of physiologic maturation of premature infants;Bakewell-Sachs;Pediatircs,2009

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Doxapram for the prevention and treatment of apnea in preterm infants;Cochrane Database of Systematic Reviews;2023-10-25